Our firm immediately saw the value that Cancer Guardian brings to our employer clients and distribution partners. We have not seen another employee benefits program of this caliber that provides a dedicated cancer strategy for managing the impacts of cancer in the workplace.. – Marcia Ellis, VP, Business Development, National Employee Benefits Marketing Organization
Cancer Guardian is an innovative benefit that can potentially save lives. People deserve affordable access to genetic testing and support services that can help them be more preventative and that could help them beat cancer if they’re ever diagnosed. This unique offering is a great way for employers to differentiate their benefits offering and show their employees that they care – Chris Krusiewicz, VP, Burnham Benefits Insurance Services
As a company and a consultant wanting to bring new solutions that can really have a positive financial impact and outcome for clients, Cancer Guardian does just that. Our clients that are using this now have peace of mind that if any one of their employees hears the word ‘cancer’, they are on a much better trajectory with this benefit in place. That’s meaningful! – Leslie Slay, Woodruff Sawyer
By 2030, cancer is expected to surpass heart disease the #1 cause of death in the U.S.(1) Cancer is the leading driver of healthcare costs and has an extensive impact on productivity and presenteeism within the workforce. Developed by industry experts, Cancer Guardian is a first-of-its-kind cancer benefit program that allows you to offer employers a competitive edge while helping them to save cost.
Cancer Guardian is an innovative benefit program that brings together the most advanced DNA testing technologies with personalized cancer support not typically covered by traditional healthcare. It is an unmatched service for employers seeking to truly differentiate their benefits offering, manage costs and support employees.
Cancer Guardian’s expert team of oncology specialists provide best-in-class training and support of the program for brokers, employers and employees. From cancer prevention to navigating the cancer treatment journey, we are dedicated to making ‘personalized medicine’ truly personal.
Cancer Guardian provides an end-to-end program for employers and employees. From education and engagement, to developing a personalized cancer plan if diagnosed, Cancer Guardian is founded on service and is a program that you can be proud to promote.
Offer your employers a program
that can change lives.
1. Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6. Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7. Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12. Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/
7SzmNmJJs1a6msorM0DZA
14. Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/
most-troubling-part-cancer-treatment-patients
